新型纤溶酶原激活剂：临床综述
New plasminogen activators: a clinical review.
作者信息
Ross A M
机构信息
Cardiovascular Research Institute, George Washington University, Washington, DC 20037, USA.
出版信息
Clin Cardiol. 1999 Mar;22(3):165-71. doi: 10.1002/clc.4960220303.
Abstract
Rapid restoration of patency of the infarct-related artery is the key to preserving myocardium and improving survival. This understanding has led to the application of genetic engineering to develop new plasminogen activators with specific clinical features. These novel activators may provide faster and more complete reperfusion in a greater number of patients, and do so with less risk of bleeding and intracranial hemorrhage. This article reviews the pharmacologic profiles and clinical performance of several novel plasminogen activators engineered from the human tissue plasminogen activator molecule or developed from animal and bacterial proteins.
摘要
迅速恢复梗死相关动脉的通畅是保护心肌和提高生存率的关键。基于这一认识，基因工程已被应用于开发具有特定临床特征的新型纤溶酶原激活剂。这些新型激活剂可能会使更多患者获得更快、更完全的再灌注，且出血和颅内出血风险更低。本文综述了几种由人组织纤溶酶原激活剂分子改造而来或基于动物及细菌蛋白研发的新型纤溶酶原激活剂的药理学特性和临床表现。
相似文献
1
New plasminogen activators: a clinical review.新型纤溶酶原激活剂：临床综述
Clin Cardiol. 1999 Mar;22(3):165-71. doi: 10.1002/clc.4960220303.
2
Thrombolytic therapy in acute myocardial infarction--selected recent developments.
Ann Hematol. 1994 Oct;69(4):S35-40. doi: 10.1007/BF02215957.
3
Newer thrombolytic drugs for acute myocardial infarction.用于急性心肌梗死的新型溶栓药物。
Indian J Exp Biol. 1998 Jan;36(1):1-15.
4
Innovative approaches to plasminogen activator therapy.纤溶酶原激活剂治疗的创新方法。
Science. 1989 Jan 6;243(4887):51-6. doi: 10.1126/science.2492113.
5
Current state of thrombolytic therapy.
Curr Cardiol Rep. 1999 Sep;1(3):212-20. doi: 10.1007/s11886-999-0025-9.
6
Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.不同溶栓方案下治疗时间对早期梗死相关动脉通畅情况的影响。ALKK研究组。
Am Heart J. 1999 Jan;137(1):34-8. doi: 10.1016/s0002-8703(99)70457-6.
7
Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
Circulation. 1990 Mar;81(3):907-13. doi: 10.1161/01.cir.81.3.907.
8
[Thrombolytic therapy of ischemic heart disease].
Nihon Naika Gakkai Zasshi. 1997 Sep 10;86(9):1625-8.
9
[Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
Wiad Lek. 1989 Apr 1;42(7):450-2.
10
[Coronary thrombolysis in patients with acute myocardial infarction].
Kokyu To Junkan. 1992 Jun;40(6):537-47.
引用本文的文献
1
Reteplase Fc-fusions produced in N. benthamiana are able to dissolve blood clots ex vivo.在 N. benthamiana 中产生的瑞替普酶 Fc 融合蛋白能够在体外溶解血栓。
PLoS One. 2021 Nov 30;16(11):e0260796. doi: 10.1371/journal.pone.0260796. eCollection 2021.
2
Thrombolytic Enzymes of Microbial Origin: A Review.微生物来源的溶栓酶：综述。
Int J Mol Sci. 2021 Sep 28;22(19):10468. doi: 10.3390/ijms221910468.
3
Thrombolytic Agents: Nanocarriers in Controlled Release.溶栓剂：控释纳米载体
Small. 2020 Oct;16(40):e2001647. doi: 10.1002/smll.202001647. Epub 2020 Aug 12.
4
Tenecteplase Versus Reteplase in Acute Myocardial Infarction: A Network Meta-Analysis of Randomized Clinical Trials.替奈普酶与瑞替普酶治疗急性心肌梗死的比较：随机临床试验的网状Meta分析
Iran J Pharm Res. 2019 Summer;18(3):1622-1631. doi: 10.22037/ijpr.2019.1100743.
5
Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion.细菌葡激酶作为第三代治疗血管闭塞药物的研究进展。
Mol Biol Rep. 2020 Jan;47(1):819-841. doi: 10.1007/s11033-019-05167-x. Epub 2019 Nov 1.
6
Scale up and pharmacokinetic study of a novel mutated chimeric tissue plasminogen activator (mt-PA) in rats.新型突变嵌合组织型纤溶酶原激活剂（mt-PA）在大鼠体内的剂量递增及药代动力学研究。
Sci Rep. 2017 Feb 22;7:43028. doi: 10.1038/srep43028.
7
Expression of a staphylokinase, a thrombolytic agent in Arabidopsis thaliana.在拟南芥中表达溶栓剂——葡激酶。
World J Microbiol Biotechnol. 2011 Jun;27(6):1341-7. doi: 10.1007/s11274-010-0583-4. Epub 2010 Oct 23.
8
Intravenous tenecteplase in acute ischemic stroke: an updated review.急性缺血性卒中的静脉注射替奈普酶：最新综述
J Neurol. 2014 Jun;261(6):1069-72. doi: 10.1007/s00415-013-7102-0. Epub 2013 Sep 15.
9
Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy.血栓靶向纤维蛋白溶解治疗的多功能纳米制剂。
Nanomedicine (Lond). 2012 Jul;7(7):1017-28. doi: 10.2217/nnm.11.179. Epub 2012 Feb 21.
10
Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA).替奈普酶（TNK-tPA）安全性和有效性评估中的问题。
Clin Cardiol. 2001 Sep;24(9):577-84. doi: 10.1002/clc.4960240903.
本文引用的文献
1
TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.急性心肌梗死中替奈普酶与加速型阿替普酶对比：心肌梗死溶栓治疗（TIMI）10B试验结果。心肌梗死溶栓治疗（TIMI）10B研究组
Circulation. 1998;98(25):2805-14. doi: 10.1161/01.cir.98.25.2805.
2
Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.溶栓治疗后早期梗死相关动脉通畅的临床预测因素：体重、吸烟史、梗死相关动脉及溶栓方案选择的重要性：GUSTO-I研究经验。全球应用链激酶和组织型纤溶酶原激活剂治疗冠状动脉闭塞。
J Am Coll Cardiol. 1998 Sep;32(3):641-7. doi: 10.1016/s0735-1097(98)00278-2.
3
Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries.瑞替普酶和阿替普酶对急性心肌梗死治疗最初24小时内血小板聚集及主要受体表达的影响。GUSTO-III研究人员。全球开放闭塞冠状动脉策略的应用研究。
J Am Coll Cardiol. 1998 Jun;31(7):1466-73. doi: 10.1016/s0735-1097(98)00172-7.
4
Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial.
Circulation. 1998 Apr 28;97(16):1549-56. doi: 10.1161/01.cir.97.16.1549.
5
Thrombolytic therapy and equivalence trials.溶栓治疗与等效性试验。
J Am Coll Cardiol. 1998 Mar 1;31(3):494-6. doi: 10.1016/s0735-1097(97)00551-2.
6
Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators.
J Am Coll Cardiol. 1998 Mar 1;31(3):487-93. doi: 10.1016/s0735-1097(97)00553-6.
7
Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent.葡萄球菌激酶：一种强效、具有独特纤维蛋白选择性的溶栓剂。
Nat Med. 1998 Mar;4(3):279-84. doi: 10.1038/nm0398-279.
8
Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence.迈向心肌再灌注治疗的新前沿：血小板地位日益凸显
Circulation. 1998 Jan 20;97(2):211-8. doi: 10.1161/01.cir.97.2.211.
9
A comparison of reteplase with alteplase for acute myocardial infarction.瑞替普酶与阿替普酶治疗急性心肌梗死的比较。
N Engl J Med. 1997 Oct 16;337(16):1118-23. doi: 10.1056/NEJM199710163371603.
10
Thrombolytic therapy.溶栓治疗
Thromb Haemost. 1997 Jul;78(1):742-6.
Zotero 插件